Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - piperacillin sodium (equivalent: piperacillin, qty 1000 mg) - injection, powder for - excipient ingredients: - piperacillin sodium is indicated for the treatment of systemic and local infections due to susceptible gram-negative and gram-positive aerobic and anaerobic bacteria. its efficacy has also been demonstrated in infections caused by some carbenicillin resistant organisms. appropriate cultures should be made before initiating treatment. therapy may be started while awaiting results of susceptibility testing. treatment should be adjusted, if necessary, when results of testing become available. piperacillin sodium is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and urinary tract) procedures, vaginal hysterectomy, and caesarean section. efficacy has not been demonstrated in biliary tract procedures. effective prophylaxis depends on the time of administration; piperacillin sodium should be given 1/2 to 1 hour before the operation so that effective levels can be achieved in the wound prior to the procedure. the exception to this rule is in caesarean section where piperacillin sodium should be administered after clamping the umbilical cord. types of infection: piperacillin sodium is recommended for the treatment of the following types of infection caused by one or more susceptible pathogens. severe systemic infections, including bacterial septicaemia, endocarditis. genitourinary tract infections (complicated and uncomplicated), including urethritis, cystitis and pyelonephritis. it is also effective in acute, uncomplicated infections caused by neisseria gonorrhoeae. respiratory tract infections (acute and chronic), including bronchitis, pneumonia, empyema and lung abscess. in patients with chronic respiratory infections or cystic fibrosis, clinical improvement has been achieved but bacterial eradication may not occur. ear, nose, throat and oral cavity infections. intra-abdominal infections, including those of the biliary tract and intra-abdominal abscess. gynaecological and obstetric infections, including endometritis, pelvic abscess and inflammation, salpingitis and puerperal infections. skin and skin structure infections, including those following infected wounds and burns, surgery and trauma. bone and joint infections. piperacillin sodium should be used at reduced dosage in adults with severely restricted kidney function (see dosage and administration). combined therapy with other antibiotics. aminoglycosides. based on in-vitro synergism and clinical results, combined therapy with piperacillin and aminoglycoside antibiotics (eg amikacin) may be used in the treatment of serious infections caused by such organisms as klebsiella, indole-positive proteus, pseudomonas and serratia. both piperacillin and the respective aminoglycoside should be given at the full therapeutic dose. cephalosporins. if piperacillin sodium is proposed to be administered concomitantly with a cephalosporin, an additive, synergistic or antagonistic antibacterial action of the two antibiotics should first be ascertained through in-vitro tests. based on in-vitro data, cefoxitin should not be given with piperacillin. piperacillin sodium has not been shown to be physically compatible with cephalosporins when mixed in the same infusion fluid. note: whenever piperacillin sodium is administered concurrently with another antibiotic, they should not be mixed in the same solution but must be administered separately.

United States - English - NLM (National Library of Medicine)

sandoz inc - piperacillin sodium (unii: m98t69q7hp) (piperacillin anhydrous - unii:9i628532gx), tazobactam sodium (unii: uxa545abtt) (tazobactam - unii:se10g96m8w) - piperacillin and tazobactam for injection is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a β-lactamase inhibitor, tazobactam, indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of the designated bacteria in the conditions listed below. appendicitis (complicated by rupture or abscess) and peritonitis caused by β-lactamase producing isolates of escherichia coli or the following members of the bacteroides fragilis group: b. fragilis , b. ovatus , b. thetaiotaomicron , or b. vulgatus . the individual members of this group were studied in fewer than 10 cases. uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by β-lactamase producing isolates of staphylococcus aureus . postpartum endometritis or pelvic inflammatory disease caused by β-lactamase producing isolates of escherichia coli . community-acquired pneumonia (

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium tablets, usp are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. warfarin sodium tablets, usp are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. warfarin sodium tablets, usp are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. anticoagulation is contraindicated in any localized or general physical condition or personal circumstance in which the hazard of hemorrhage might be greater than the potential clinical benefits of anticoagulation, such as: warfarin sodium tablets, usp are contraindicated in women who are or may become pregnant because the drug passes through the placental barrier and may cause fatal hemorrhage to the fetus . furthermore, there have been reports of birth malformations in children born to m

Namibia - English - Namibia Medicines Regulatory Council

adcock ingram critical care (pty) ltd - cefoxitin sodium - injection - each vial contains cefoxitin sodium equiv. to cefoxitin 1,0g

Namibia - English - Namibia Medicines Regulatory Council

adcock ingram critical care (pty) ltd - cefoxitin sodium - injection - each vial contains cefoxitin sodium equiv. to cefoxitin 2,0g

Ireland - English - HPRA (Health Products Regulatory Authority)

viatris limited - piperacillin sodium; tazobactam (as sodium salt) - powder for solution for infusion - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

viatris limited - piperacillin sodium; tazobactam (as sodium salt) - powder for solution for infusion - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Philippines - English - FDA (Food And Drug Administration)

b. braun medical supplies, inc.; distributor: b. braun medical supplies, inc. - cefoxitin (as sodium) , dextrose - solution for injection (iv infusion) - 1g/ 4%

Philippines - English - FDA (Food And Drug Administration)

aglobal care inc. - cefoxitin (as sodium) - powder for injection (im/iv) - 1g

Philippines - English - FDA (Food And Drug Administration)

aglobal care, inc. - cefoxitin (as sodium) - powder for injection im/iv - 1g